Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

NCT06315972 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: clemastine (8 mg/day)
DRUG: Placebo

Sponsor

LMU Klinikum